PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design-Reference-Cited by-同舟云学术

PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design

Published:2022-07-11 Issue:12 Volume:63 Page:2816-2831
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Broglio Kristine¹^ORCID,Kostakoglu Lale²^ORCID,Ward Carol³^ORCID,Mattiello Federico³,Sahin Denis³^ORCID,Nielsen Tina³,McGlothlin Anna¹^ORCID,Elliott Corrine F.¹^ORCID,Witzig Thomas⁴^ORCID,Sehn Laurie H.⁵^ORCID,Trnĕný Marek⁶^ORCID,Vitolo Umberto⁷^ORCID,Martelli Maurizio⁸^ORCID,Foster Margaret⁹^ORCID,Wendelberger Barbara¹^ORCID,Nowakowski Grzegorz⁴,Berry Donald A.¹^ORCID

Affiliation:

1. Berry Consultants, LLC, Austin, TX, USA

2. Department of Nuclear Medicine, University of Virginia, Charlottesville, VA, USA

3. F. Hoffmann-La Roche Ltd., Basel, Switzerland

4. Mayo Clinic, Rochester, MN, USA

5. BC Cancer Agency, Vancouver, BC, Canada

6. Charles University and General University Hospital, Prague, Czech Republic

7. Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

8. Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy

9. University Libraries, Texas A&M University, College Station, TX, USA

Funder

Berry Consultants, LLC

Roche/Genentech and Teva

Abbvie

Acerta

Amgen

Apobiologix

Astra Zeneca

Celgene

Chugai

Gilead

Incyte

Janssen

Kite

Karyopharm

Lundbeck

Merck

Morphosys

Roche/Genentech

Sandoz

Seattle Genetics

Servier

Teva

Takeda

TG Therapeutics

Verastem

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2095624

Reference53 articles.

1. Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?

2. The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy

3. End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma

4. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EXABS-137-LYM Circulating Tumor DNA In Lymphoma: When Will It Be Ready for Prime Time?;Clinical Lymphoma Myeloma and Leukemia;2023-09